We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-4 of 4

Sandoz Requests Supreme Court Review of the Federal Circuit’s Interpretation of Biosimilar Law
  • Baker & Hostetler LLP
  • USA
  • February 18 2016

On February 16, 2016, Sandoz Inc. filed a petition for a writ of certiorari with the U.S. Supreme Court, asking the Court to review the Federal

Federal Circuit confirms both new biosimilar bring-to-market procedural option and additional six-month exclusivity period for brand-name biologics
  • Baker & Hostetler LLP
  • USA
  • July 27 2015

On July 21, 2015, brand-name biologics companies and companies developing biosimilars received a split in a significant decision with industry-wide

Ronald C. Kern Jr.
  • Baker & Hostetler LLP